Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Clinical trial NCT06954116 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06954116
- Sponsor
- Tongji Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-01
- Primary completion
- 2028-12-31
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.